Skip to Content
Merck
CN

47583

Fmoc-Lys(Alloc)-OH

≥95.0% (HPLC), for peptide synthesis

Synonym(s):

Nα-Fmoc-Nε-Alloc-L-lysine

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C25H28N2O6
CAS Number:
Molecular Weight:
452.50
UNSPSC Code:
12352209
eCl@ss:
32160406
PubChem Substance ID:
NACRES:
NA.26
Beilstein/REAXYS Number:
5893081
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Product Name

Fmoc-Lys(Alloc)-OH, ≥95.0% (HPLC)

Quality Level

assay

≥95.0% (HPLC)

form

powder

optical activity

[α]20/D −12±1°, c = 1% in DMF

reaction suitability

reaction type: Fmoc solid-phase peptide synthesis

technique(s)

NMR: suitable

color

beige

application(s)

peptide synthesis

functional group

Fmoc

storage temp.

2-8°C

SMILES string

OC(=O)[C@H](CCCCNC(=O)OCC=C)NC(=O)OCC1c2ccccc2-c3ccccc13

InChI

1S/C25H28N2O6/c1-2-15-32-24(30)26-14-8-7-13-22(23(28)29)27-25(31)33-16-21-19-11-5-3-9-17(19)18-10-4-6-12-20(18)21/h2-6,9-12,21-22H,1,7-8,13-16H2,(H,26,30)(H,27,31)(H,28,29)/t22-/m0/s1

InChI key

OJBNDXHENJDCBA-QFIPXVFZSA-N



Still not finding the right product?

Explore all of our products under Fmoc-Lys(Alloc)-OH


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Mireia Hoyos-Nogués et al.
ACS applied materials & interfaces, 9(26), 21618-21630 (2017-06-09)
In dentistry and orthopedics, it is well accepted that implant fixation is a major goal. However, an emerging concern is bacterial infection. Infection of metallic implants can be catastrophic and significantly reduce patient quality of life. Accordingly, in this work
Petro P Czupiel et al.
Journal of controlled release : official journal of the Controlled Release Society, 305, 210-219 (2019-05-10)
Currently, there are limited treatment options for multi-drug resistant breast cancer. Lipid-modified cationic peptides have the potential to reach the mitochondria, which are attractive targets for the treatment of multi-drug resistant (MDR) breast cancer; yet, little is known about their



Global Trade Item Number

SKUGTIN
47583-5G-F04061832361925
47583-1G-F04061826222621